Base Excision Repair

Base Excision Repair (BER) is the DNA repair pathway responsible for correcting small-scale, non-helix-distorting base lesions — oxidized, alkylated, deaminated, or otherwise chemically modified individual bases, as well as abasic sites and certain single-strand breaks — through a sequential process of lesion recognition, base removal, and localized DNA resynthesis. It is one of the most frequently engaged repair pathways in any dividing cell given the sheer volume of spontaneous base damage arising from normal cellular metabolism, and its dysregulation carries direct significance for cancer cell genome stability and treatment response.

The Nature of Lesions Repaired by BER

Oxidative Base Damage

Reactive oxygen species generated as byproducts of normal cellular respiration continuously damage DNA bases, with 8-oxoguanine representing one of the most common and best-characterized oxidative lesions — if left unrepaired, 8-oxoguanine mispairs with adenine during replication, producing a G:C to T:A transversion mutation, making its efficient repair essential to limiting the ongoing mutational burden imposed by normal cellular metabolism.

Alkylation and Deamination Damage

Alkylating agents, both endogenous metabolic byproducts and exogenous chemical exposures, add alkyl groups to DNA bases, distorting their normal base-pairing behavior; spontaneous or enzymatic deamination similarly converts one base into another (cytosine to uracil, for instance), both producing lesions that BER is specifically equipped to recognize and correct.

Abasic Sites

Spontaneous hydrolysis of the bond between a base and the sugar-phosphate backbone, or as an intermediate generated during BER's own base-removal step, produces an abasic (apurinic/apyrimidinic) site lacking a base entirely — these sites are themselves substrates for continued BER processing and, if left unrepaired, block replication and transcription machinery.

The Stepwise BER Mechanism

Lesion Recognition by DNA Glycosylases

BER is initiated by one of a family of DNA glycosylases, each specialized to recognize a particular category of base damage, which cleaves the glycosidic bond linking the damaged base to the sugar-phosphate backbone, excising the damaged base itself and leaving behind an abasic site — this substrate specificity across multiple distinct glycosylases is what allows BER to address such a chemically diverse range of base lesions through a shared downstream mechanism.

AP Endonuclease Processing

AP endonuclease 1 (APE1) recognizes the resulting abasic site and incises the DNA backbone immediately adjacent to it, generating a single-strand break with a free 3'-hydroxyl group that serves as the priming substrate for the subsequent DNA synthesis step.

Short-Patch Versus Long-Patch Resynthesis

BER proceeds through one of two sub-pathways distinguished by how much new DNA is synthesized to fill the resulting gap: the short-patch pathway, in which DNA polymerase β replaces a single nucleotide and DNA ligase III (in complex with XRCC1) seals the remaining nick, and the long-patch pathway, in which DNA polymerase δ or ε synthesizes a longer replacement stretch of several nucleotides, displacing the old strand as a flap that is subsequently removed by FEN1 before ligation by DNA ligase I.

Coordination by Scaffold Proteins

XRCC1 functions as a central scaffold protein coordinating the short-patch BER pathway, physically interacting with multiple downstream enzymes to ensure the sequential steps proceed efficiently and that reaction intermediates — themselves potentially genotoxic single-strand breaks — do not persist and accumulate unrepaired.

BER's Relationship to Genome Stability

Managing the Bulk of Spontaneous DNA Damage

Because oxidative and other base lesions arise continuously and in far greater absolute number than the double-strand breaks addressed by homologous recombination or non-homologous end joining, BER is arguably the highest-throughput repair pathway operating in any given cell, and even modest deficiencies in its efficiency can translate into a meaningfully elevated genome-wide point mutation rate over time.

BER Intermediates as a Source of Risk

Because the BER process necessarily creates transient single-strand breaks and abasic sites as repair intermediates, inefficient or poorly coordinated BER can itself become a source of genomic instability if these intermediates persist or are converted into double-strand breaks during DNA replication, illustrating that BER is not a risk-free process but one whose own intermediate states require careful downstream handling.

BER Dysregulation in Cancer

Altered Glycosylase Expression and Function

Variation in the expression or activity of specific DNA glycosylases has been observed across cancer types, with implications for the specific mutational signatures a tumor accumulates — deficient repair of oxidative lesions, for instance, is expected to elevate the characteristic G:C to T:A transversion signature associated with unrepaired 8-oxoguanine specifically.

Contribution to Overall Mutational Burden

Because BER handles the majority of spontaneous base damage, its efficiency (or deficiency) contributes to the baseline point mutation rate against which the more dramatic structural and numerical instability mechanisms discussed elsewhere in cancer genome instability operate, representing a distinct, complementary axis of genomic alteration accumulation.

Therapeutic Relevance

PARP as a BER-Associated Target

Poly (ADP-ribose) polymerase (PARP), while not a core BER enzyme itself, plays an important role in detecting and facilitating repair of the single-strand breaks that arise as BER intermediates — this connection underlies part of the mechanistic rationale for PARP inhibitor sensitivity in tumors with additional repair deficiencies, since unrepaired single-strand breaks that would normally be resolved with PARP assistance can be converted into more dangerous double-strand breaks during replication when PARP function is pharmacologically blocked.

BER Enzyme Targeting in Combination Strategies

Direct inhibition of specific BER components, particularly in combination with DNA-damaging chemotherapy or radiation, has been explored as a strategy to sensitize cancer cells by preventing them from efficiently repairing the base damage such treatments induce, exploiting BER's central role in managing that specific category of therapeutic DNA damage.

Practical Significance

Base Excision Repair is the primary cellular mechanism for correcting the high-volume, chemically diverse burden of spontaneous base damage arising from normal cellular metabolism, proceeding through glycosylase-mediated lesion recognition, AP endonuclease processing, and short- or long-patch DNA resynthesis. Its efficiency shapes the baseline point mutation rate of a cell's genome, its intermediates connect mechanistically to broader genome stability considerations including PARP-dependent single-strand break management, and its dysregulation or therapeutic exploitation represents a significant and actively studied dimension of cancer cell DNA damage response biology.